Author details

Full Name

Kostyantyn Krysan

Affiliation

David Geffen School of Medicine at University of California at Los Angeles

ORCID

Career Start Year

1999

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37477508	Single-Cell Characterization of Pulmonary Nodules Implicates Suppression of Immunosurveillance across Early Stages of Lung Adenocarcinoma.	Cancer Res	2023
37716353	The Liquid Biopsy Consortium: Challenges and opportunities for early cancer detection and monitoring.	Cell Rep Med	2023
37730274	CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity.	J Immunother Cancer	2023
37399400	Comprehensive tissue deconvolution of cell-free DNA by deep learning for disease diagnosis and monitoring.	Proc Natl Acad Sci U S A	2023
33972311	Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing.	Cancer Discov	2021
33853830	Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer.	Cancer Res	2021
34755131	Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma.	Cell Rep Med	2021
34001525	Early Diagnosis and Screening for Lung Cancer.	Cold Spring Harb Perspect Med	2021
32127587	Author Correction: Chronic IL-1Î²-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer.	Sci Rep	2020
31941995	Chronic IL-1Î²-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer.	Sci Rep	2020
32891189	Organoids Model Transcriptional Hallmarks of Oncogenic KRAS Activation in Lung Epithelial Progenitor Cells.	Cell Stem Cell	2020
33004476	Immunosurveillance and Regression in the Context of Squamous Pulmonary Premalignancy.	Cancer Discov	2020
32856614	Lung Cancer and Immunity Markers.	Cancer Epidemiol Biomarkers Prev	2020
32194893	FRA1 contributes to MEK-ERK pathway-dependent PD-L1 upregulation by KRAS mutation in premalignant human bronchial epithelial cells.	Am J Transl Res	2020
31142513	The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy.	Cancer Res	2019
31015447	Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions.	Nat Commun	2019
29431637	Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells.	Cancer Res	2018
29510677	Summarizing performance for genome scale measurement of miRNA: reference samples and metrics.	BMC Genomics	2018
28754664	Identification of a Human Airway Epithelial Cell Subpopulation with Altered Biophysical, Molecular, and Metastatic Properties.	Cancer Prev Res (Phila)	2017
28335812	CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA.	Genome Biol	2017
28099841	Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.	Cell Rep	2017
24253315	A novel molecular pathway for Snail-dependent, SPARC-mediated invasion in non-small cell lung cancer pathogenesis.	Cancer Prev Res (Phila)	2014
26523208	Combination Treatment with Apricoxib and IL-27 Enhances Inhibition of Epithelial-Mesenchymal Transition in Human Lung Cancer Cells through a STAT1 Dominant Pathway.	J Cancer Sci Ther	2014
24913817	Loss of miR125a expression in a model of K-ras-dependent pulmonary premalignancy.	Cancer Prev Res (Phila)	2014
24469837	PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC.	Mol Cancer Res	2014
23977408	Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer.	Am J Transl Res	2013
24274066	IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer.	J Exp Clin Cancer Res	2013
21922183	The inflammatory tumor microenvironment, epithelial mesenchymal transition and lung carcinogenesis.	Cancer Microenviron	2012
21654877	Elevated levels of CXC chemokine connective tissue activating peptide (CTAP)-III in lung cancer patients.	Am J Transl Res	2011
19789323	Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma.	Clin Cancer Res	2009
18303428	Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance.	J Thorac Oncol	2008
18303430	Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.	J Thorac Oncol	2008
17381414	Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC.	Future Oncol	2007
17944566	Inflammation and lung carcinogenesis: applying findings in prevention and treatment.	Expert Rev Anticancer Ther	2007
16740761	A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.	Clin Cancer Res	2006
16712449	The potential and rationale for COX-2 inhibitors in lung cancer.	Anticancer Agents Med Chem	2006
16707460	Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.	Cancer Res	2006
16024629	Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner.	Cancer Res	2005
16278387	Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.	Clin Cancer Res	2005
15908458	PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells.	J Leukoc Biol	2005
16098242	Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer.	Clin Lung Cancer	2005
14597555	COX-2-dependent stabilization of survivin in non-small cell lung cancer.	FASEB J	2004
15296859	Multifaceted roles of cyclooxygenase-2 in lung cancer.	Drug Resist Updat	2004
15374967	Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer.	Cancer Res	2004
15374938	Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer.	Cancer Res	2004
15494493	Prostaglandin E2-dependent enhancement of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration through extracellular matrix.	J Immunol	2004
14996749	Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer.	Cancer Res	2004
15109912	Platelet derived growth factor (PDGF)-induced reactive oxygen species in the lens epithelial cells: the redox signaling.	Exp Eye Res	2004
15136466	Cyclooxygenase-2-dependent expression of survivin in non-small cell lung cancer.	Chest	2004
12591723	Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells.	Cancer Res	2003

1 - 50 of 56

Zhixin Qiu

UPMC Hillman Cancer Center

Career Start Year 2012

Number of shared co-authors 0

Fei Li

Shanghai Pulmonary Hospital, Tongji University School of Medicine

Career Start Year 2010

Number of shared co-authors 0

Mary Zhang

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Career Start Year 2010

Number of shared co-authors 0

Chad V Pecot

University of North Carolina at Chapel Hill

Career Start Year 2009

Number of shared co-authors 1

Shingo Sakashita

National Cancer Center Exploratory Oncology Research & Clinical Trial Center

Career Start Year 2008

Number of shared co-authors 0

Xi Liu

College of Biology and Food, Shangqiu Normal University

Career Start Year 2007

Number of shared co-authors 2

Young K Song

National Cancer Institute, National Institutes of Health

Career Start Year 2007

Number of shared co-authors 0

Lixia Diao

The University of Texas MD Anderson Cancer Center

Career Start Year 2003

Number of shared co-authors 3

Hae-Yun Jung

College of Life Science, CHA University

Career Start Year 2003

Number of shared co-authors 0

Xin Yang

Peking University Cancer Hospital & Institute

Career Start Year 2002

Number of shared co-authors 0

Hye Jin You

Research Institute, National Cancer Center

Career Start Year 2000

Number of shared co-authors 0

Jianjun Shen

The University of Texas MD Anderson Cancer Center

Career Start Year 1998

Number of shared co-authors 2

Roya Navab

Princess Margaret Cancer Centre, University Health Network

Career Start Year 1997

Number of shared co-authors 0

Patrick Micke

Uppsala University

Career Start Year 1997

Number of shared co-authors 0

Ni Liu

Princess Margaret Cancer Centre, University Health Network, University of Toronto

Career Start Year 1997

Number of shared co-authors 0

Hai Hu

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

Career Start Year 1996

Number of shared co-authors 1

Chang-Qi Zhu

Princess Margaret Cancer Centre, University Health Network

Career Start Year 1996

Number of shared co-authors 1

Peter S Hammerman

Novartis Institutes for BioMedical Research

Career Start Year 1996

Number of shared co-authors 1

Ping Yang

Mayo Clinic

Career Start Year 1996

Number of shared co-authors 1

Michael Peyton

Hamon Center for Therapeutic Oncology Research, UT Southwestern Medical Center

Career Start Year 1994

Number of shared co-authors 3

Sichuan Xi

Center for Cancer Research, National Cancer Institute, National Institutes of Health

Career Start Year 1994

Number of shared co-authors 0

Pierre P Massion

Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

Career Start Year 1993

Number of shared co-authors 5

David N Watkins

Research Institute in Oncology and Hematology

Career Start Year 1991

Number of shared co-authors 0

Enhua Wang

The First Hospital and College of Basic Medical Sciences, China Medical University

Career Start Year 1990

Number of shared co-authors 0

Charles M Rudin

Memorial Sloan Kettering Cancer Center

Career Start Year 1989

Number of shared co-authors 4

David S Schrump

Center for Cancer Research, National Cancer Institute

Career Start Year 1988

Number of shared co-authors 0

Wei Zhang

The University of Texas MD Anderson Cancer Center

Career Start Year 1988

Number of shared co-authors 0

Helen J Ross

Mayo Clinic

Career Start Year 1982

Number of shared co-authors 0

David M Jablons

University of California, USA Cardiovascular Research Institute san francisco

Career Start Year 1981

Number of shared co-authors 2

Ming-Sound Tsao

University Health Network, University of Toronto

Career Start Year 1972

Number of shared co-authors 3

row(s) 1 - 30 of 30

Steven M Dubinett

David Geffen School of Medicine at university of california los angeles

Co-authored papers 49

Michael C Fishbein

Co-authored papers 8

David Elashoff

David Geffen School of Medicine at University of California los angeles

Co-authored papers 8

Avrum Spira

Boston University School of Medicine

Co-authored papers 7

Edward B Garon

David Geffen School of Medicine, University of California Los Angeles

Co-authored papers 7

John D Minna

University of Texas Southwestern Medical Center at Dallas

Co-authored papers 5

Jane Yanagawa

David Geffen School of Medicine, University of California Los Angeles

Co-authored papers 5

Denise R Aberle

David Geffen School of Medicine at university of california los angeles

Co-authored papers 4

Eileen Fung

Co-authored papers 3

Marc E Lenburg

Co-authored papers 3

Maie A St John

Co-authored papers 3

Lee Goodglick

Co-authored papers 3

Yonggang Zhou

David Geffen School of Medicine, University of California at Los Angeles

Co-authored papers 2

Wenyuan Li

Harvard Medical School

Co-authored papers 2

Clara E Magyar

David Geffen School of Medicine, University of California at Los Angeles

Co-authored papers 2

Xianghong Jasmine Zhou

David Geffen School of Medicine, University of California at Los Angeles

Co-authored papers 2

Nicholas J Jackson

St Thomas' Hospital

Co-authored papers 1

Jianjun Zhang

The University of Texas MD Anderson Cancer Center

Co-authored papers 1

Aaron Lisberg

Jonsson Comprehensive Cancer Center, university of california los angeles

Co-authored papers 1

Leonora Balaj

Massachusetts General Hospital

Co-authored papers 1

Nickolas Papadopoulos

Co-authored papers 1

Robert B Cameron

University of California los angeles

Co-authored papers 1

William Hsu

American Medical Informatics Association, IEEE, Johns Hopkins University, Radiological Society of North America, University of California Los Angeles, University of California, Los Angeles

Co-authored papers 1

Andrew Emili

Boston University School of Medicine, Boston University

Co-authored papers 1

Arjan Gower

David Geffen School of Medicine at University of California at Los Angeles

Co-authored papers 1

David S K Lu

University of California, Los Angeles David Geffen School of Medicine

Co-authored papers 1

Frank Alber

University of California los angeles